丙型肝炎藥物市場規模、佔有率及成長分析（按藥物類別、給藥途徑、疾病類型和地區）－產業預測，2025 年至 2032 年

預計 2023 年全球丙型肝炎治療市場價值將達到 125 億美元，並從 2024 年的 130.2 億美元成長到 2032 年的 180.5 億美元，預測期內（2025-2032 年）的複合年成長率為 4.2%。

全球丙型肝炎治療市場正經歷著動態成長，這得益於人們認知的提高、診斷技術的進步和有效治療方案的出現。丙型肝炎盛行率的上升推動了對抗病毒治療的需求，尤其是在老年人等弱勢群體中。政府和醫療機構為消滅病毒所做的努力進一步促進了市場擴張。公共衛生宣傳活動越來越注重對高風險族群進行疾病和可用治療方法的教育。技術創新極大地改變了市場，例如直接抗病毒藥物 (DAA) 的出現，其治癒率超過 95%，縮短了治療時間，並最大限度地減少了副作用。此外，泛基因型 DAA 和固定劑量組合藥物等創新提高了治療的便利性和依從性，從而能夠為更廣泛的患者群體提供有效的治療。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

丙型肝炎藥物市場規模（依藥物類別分類）及複合年成長率（2025-2032）

• 市場概覽
• 直接抗病毒藥物
  • NS3/4A蛋白酶抑制劑
  • NS5A抑制劑
  • NS5B聚合酵素抑制劑
• 聯合治療
• 干擾素
• 其他

丙型肝炎藥物市場規模（依給藥途徑分類）及複合年成長率（2025-2032）

• 市場概覽
• 口服
• 注射
• 其他

丙型肝炎藥物市場規模（依疾病類型分類）及複合年成長率（2025-2032）

• 市場概覽
• 慢性C型肝炎
• 急性C型肝炎

丙型肝炎藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• Pfizer（USA）
• AbbVie（USA）
• Gilead Sciences（USA）
• Roche（Switzerland）
• Johnson and Johnson（USA）
• Novo Nordisk（Denmark）
• Hepion Pharmaceutical（USA）
• Vir Biotechnology（USA）
• Teva Pharmaceutical（Israel）
• Bristol Myers Squibb（USA）
• Merck（USA）
• AstraZeneca（UK）
• GlaxoSmithKline（UK）
• Sanofi（France）

結論和建議

Global Hepatitis C Drugs Market size was valued at USD 12.5 Billion in 2023 poised to grow from USD 13.02 in 2024 to USD 18.05 Billion by 2032, growing at a CAGR of 4.2% in the forecast period (2025-2032).

The global hepatitis C drugs market is experiencing dynamic growth, fueled by increased awareness, enhanced diagnostic advancements, and effective treatment options. The rising prevalence of hepatitis C infections is propelling demand for antiviral therapies, especially among demographics with higher infection rates, such as the elderly. Efforts from governments and healthcare organizations aimed at eradicating the virus further contribute to market expansion. Public health campaigns are increasingly focusing on educating high-risk populations about the disease and available treatments. Technological advancements have transformed the market with the emergence of direct-acting antivirals (DAAs) that achieve over 95% cure rates, reduce treatment durations, and minimize side effects. Innovations like pan-genotypic DAAs and fixed-dose combinations enhance treatment convenience and compliance, ensuring broader access to effective therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatitis C Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatitis C Drugs Market Segments Analysis

The hepatitis C drugs market is segmented based on drug class, routes of administration, disease type and region. In terms of drug class, the market is segmented into direct acting antivirals (NS3/4A protease inhibitor, NS5A inhibitor, NS5B polymerase inhibitor), combination therapy, interferons, and others. Based on routes of administration, the market is segmented into oral, injectable, and others. Based on disease type, the market is bifurcated into chronic hepatitis C and acute hepatitis C. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Hepatitis C Drugs Market

The growing prevalence of hepatitis C worldwide is significantly boosting the need for effective therapies, driven by factors such as intravenous drug use and unsafe medical procedures. As more individuals are diagnosed with this viral infection, the urgency for advanced treatment solutions intensifies. Additionally, increased awareness about the disease and its potential complications further propels the market for hepatitis C medications. Healthcare providers are focusing on improving screening and treatment options, leading to a greater demand for innovative drug formulations and therapies in the market, reflecting an overarching commitment to managing and ultimately eradicating this public health concern.

Restraints in the Global Hepatitis C Drugs Market

A major challenge facing the global hepatitis C drugs market is the high cost of direct-acting antiviral (DAA) medications, which remains a hurdle for widespread treatment in regions where healthcare budgets are constrained. In many countries, limited financial resources hinder healthcare systems from providing universal access to these essential drugs, despite some efforts to lower prices through competition and government negotiations. As a result, the economic burden associated with hepatitis C treatment continues to restrict access, leaving many patients without the necessary therapies and impeding progress toward eradicating the disease on a global scale.

Market Trends of the Global Hepatitis C Drugs Market

The global Hepatitis C drugs market is witnessing a marked transition toward affordable Direct-Acting Antivirals (DAAs) and generic formulations, driven by the expiration of patents and the implementation of voluntary licensing agreements. This trend is particularly significant in low- and middle-income countries, where access to cost-effective treatment options is crucial for controlling the virus. Enhanced affordability is pivotal, aligning with the World Health Organization's goals for Hepatitis C elimination, as it fosters increased treatment rates and expands the positive impact on public health. The increased availability of generics is reshaping the competitive landscape and facilitating broader access to lifesaving therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Hepatitis C Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Direct Acting Antiviral
  • NS3/4A Protease Inhibitor
  • NS5A Inhibitor
  • NS5B Polymerase Inhibitor
• Combination Therapy
• Interferons
• Others

Global Hepatitis C Drugs Market Size by Routes of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Others

Global Hepatitis C Drugs Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Chronic Hepatitis C
• Acute Hepatitis C

Global Hepatitis C Drugs Market Size & CAGR (2025-2032)

• North America (Drug Class, Routes of Administration, Disease Type)
  • US
  • Canada
• Europe (Drug Class, Routes of Administration, Disease Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Routes of Administration, Disease Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Routes of Administration, Disease Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Routes of Administration, Disease Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson and Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceutical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vir Biotechnology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations